Literature DB >> 29774880

Leukocyte miR-223-3p is not associated with 
altered platelet responses to clopidogrel in patients with coronary artery disease.

Wenjian Xie1, Qian Yin2, Mengran Zhang2, Shengnan Li3, Shaoliang Chen1.   

Abstract

OBJECTIVE: To investigate the potential correlation between miR-223 level in leukocytes and platelet responses to clopidogrel in patients with coronary artery disease.

Methods: A cohort of 188 outpatients, who conducted percutaneous coronary intervention (PCI) and received dual antiplatelet therapy, were recruited. The patient's electronic health data were collected, and their blood samples were obtained for measurement of adenosine diphosphate (ADP)-induced whole-blood platelet aggregation. Extreme cases of platelet responses to clopidogrel (ultra- vs. non-responder) were measured with miR-223-3p levels in leukocytes.

Results: Both groups had similar miR-223-3p levels in leukocytes. There were no significant differences in other demographic and clinical data except for metrics of ADP-induced whole-blood platelet aggregation between the 2 group.

Conclusion: MiR-223-3p in peripheral leukocytes is not associated with the altered platelet responses to clopidogrel in PCI outpatients.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29774880     DOI: 10.11817/j.issn.1672-7347.2018.04.014

Source DB:  PubMed          Journal:  Zhong Nan Da Xue Xue Bao Yi Xue Ban        ISSN: 1672-7347


  3 in total

1.  miR-223-3p inhibits the progression of atherosclerosis via down-regulating the activation of MEK1/ERK1/2 in macrophages.

Authors:  Daofeng You; Qiuge Qiao; Katsushige Ono; Mei Wei; Wenyun Tan; Cuihua Wang; Yangong Liu; Gang Liu; Mingqi Zheng
Journal:  Aging (Albany NY)       Date:  2022-02-24       Impact factor: 5.682

Review 2.  Circulating and Platelet MicroRNAs in Cardiovascular Risk Assessment and Antiplatelet Therapy Monitoring.

Authors:  Grzegorz Procyk; Dominika Klimczak-Tomaniak; Grażyna Sygitowicz; Mariusz Tomaniak
Journal:  J Clin Med       Date:  2022-03-22       Impact factor: 4.241

3.  High-Throughput MicroRNA Profiling of Vitreoretinal Lymphoma: Vitreous and Serum MicroRNA Profiles Distinct from Uveitis.

Authors:  Teruumi Minezaki; Yoshihiko Usui; Masaki Asakage; Masakatsu Takanashi; Hiroyuki Shimizu; Naoya Nezu; Akitomo Narimatsu; Kinya Tsubota; Kazuhiko Umazume; Naoyuki Yamakawa; Masahiko Kuroda; Hiroshi Goto
Journal:  J Clin Med       Date:  2020-06-12       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.